German drugmaker Boehringer Ingelheim is launching a new artificial intelligence and machine learning centre in London, committing £150 million over ten years to expand its AI capabilities in pharmaceutical research and development, according to Reuters.

The London facility, located near King's Cross station in the city's Knowledge Quarter, will become Boehringer Ingelheim's fourth specialist AI location globally, joining existing centres in Austria, Germany, and the United States. The Knowledge Quarter is home to a concentration of major AI companies including OpenAI, Google, and Meta, reinforcing London's standing as a leading destination for technology-driven life sciences investment.

The centre will focus on developing targeted medicines for patients with unmet medical needs, applying advanced computing methods including algorithms, data analysis, and machine learning to improve processes and accelerate drug discovery across Boehringer Ingelheim's global research operations.

Paola Casarosa, Global Head of Innovation Unit at Boehringer Ingelheim, said: "The UK has a strong legacy in AI, and the government's continued commitment to advancing data-driven innovation in life sciences and healthcare makes it an ideal location."

The London investment positions Boehringer Ingelheim at the centre of the UK's growing AI life sciences ecosystem, as Britain actively seeks to establish itself as a global hub for cutting-edge pharmaceutical research and innovation.

Pharmaceutical companies are increasingly deploying AI to reduce the most time-consuming elements of drug development, from trial recruitment and site selection to regulatory documentation, even as industry observers acknowledge the technology has yet to fulfil its promise in discovering major new molecules. Swiss drugmaker Roche has also recently expanded its AI computing capacity with more than 2,100 Nvidia chips.

Read the full article for comprehensive details on Boehringer Ingelheim's London AI centre and investment plans.